Zivo Bioscience Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2024

Registrant’s Telephone Number, Including Area Code: (248) 452-9866

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the annual meeting of shareholders (the “Annual Meeting”) of Zivo Bioscience, Inc. (the “Company”) held on June 11, 2024, shareholders (i) elected one Class II director to the Company’s Board of Directors to serve a three-year term until the 2027 annual meeting of shareholders, (ii) ratified the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024, and (iii) approved (on an advisory basis) the compensation of the Company’s named executive officers. These proposals are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2024.

A total of 1,862,320 shares of the Company’s common stock were present at the meeting in person or by proxy, which represents approximately 66.4% of the shares of common stock outstanding as of the record date for the Annual Meeting.

According to the final vote, the Company’s stockholders approved all three proposals. The final results of the voting are shown below:

Proposal 1—Election of One Class II Director

Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm

Proposal 3—Approval (on an Advisory Basis) of the Compensation of the Company’s Named Executive Officers

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 13, 2024